Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill.

Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in Europe Strong strategic fit with Eton’s existing pediatric endocrinology focus Amglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) Potential New Drug

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million , or $0.02 per diluted share Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) Q3 2024 product sales increased 40% over Q3 2023, representing 15 th straight quarter of sequential product

- Product has patent protection through 2043 - - Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on

DEER PARK, Ill. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial

Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric Endocrinology Portfolio DEER PARK, Ill. , Oct. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or

DEER PARK, Ill. , Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C.

Product sales and royalty revenue of $9.1 million , representing 40% growth over Q2 2023 and the 14 th straight quarter of sequential product sales growth New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA date Q2

DEER PARK, Ill. , July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill. , July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on